Breaking News
Concord Health Partners Expands Senior Team & Opens Nashville Office
Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced that Erik Larsen and Derek Schmidt have joined the firm as Managing Directors. The Firm also announced the opening of a Nashville, Tennessee office.
Larsen joins Concord from HCA Healthcare, Inc., where he was most recently Vice President of the Special Assets Group. As Managing Director, Larsen will leverage his more than 20 years of experience in healthcare investing, investment banking and corporate development to help source new opportunities and enhance the firm’s investment strategy and execution. He will report to James Olsen, Founder and Managing Partner of Concord, and be located in the Firm’s new Nashville office.
Schmidt was most recently the Director of Private Equity for Marquette Associates, where he directed private equity and venture capital program construction, including manager selection, co-investment and secondary deployment. At Concord, he will lead the firm’s capital formation efforts and focus on Concord’s investor relations, single asset funds and the buildout of potential new strategies. He will report to Olsen and be located in Nashville.
“Our mission at Concord is to build a broad healthcare investment platform that allows us to extend our reach and take advantage of a broader universe of opportunities that create meaningful value for our investors and portfolio companies. These exciting team additions and the opening of our Nashville office help achieve that goal,” said Olsen. “Adding Erik and Derek’s experience further institutionalizes our team, and I look forward to working closely with them both to continue strengthening our investment process and working with our strategic LPs to accelerate growth at our portfolio companies.”
“Concord’s strategy, expertise and unique LP base have quickly proven to be differentiators in the healthcare investing space,” said Larsen. “I am excited about the opportunity to strategically build the team and expand my network in Nashville to help Concord continue to identify and grow innovative businesses and solutions that improve quality of care, reduce cost, and enhance access to care.”
“I have known the team at Concord for a number of years in my role underwriting investor commitments, and I am eager to join the team at such an exciting time for the firm and for healthcare investing more broadly,” said Schmidt. “I look forward to partnering and engaging with the firm’s advisors and strategic LPs to proactively identify new opportunities and avenues to drive value across the care continuum.”
Schmidt and Larsen join Brian Gragnolati, who currently serves as President and CEO of Atlantic Health System and is former Chairman of the Board of Trustees of the American Hospital Association, as recent additions to the Concord team. As announced on July 11, Gragnolati joined the firm as Executive Partner, where he will source new investment opportunities, support management teams and accelerate the growth of Concord portfolio companies through commercial introductions across the Concord network of strategic relationships.
“Nashville has become a true hub of healthcare innovation and talent,” Olsen added. “Establishing a presence there will allow us to better identify, diligence and execute while we continue our growth and evolution as a firm. We look forward to benefitting from having both Erik and Derek on the ground there to help us build our team and capabilities in the market.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more